{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670318352082816.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1002/ana.20222"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fana.20222"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.20222"}},{"identifier":{"@type":"PMID","@value":"15389898"}},{"identifier":{"@type":"NAID","@value":"30008830718"}}],"dc:title":[{"@value":"Ganglioside complexes as new target antigens in Guillain–Barré syndrome"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title><jats:p>Antibodies specific for a complex of gangliosides GD1a and GD1b (GD1a/GD1b) were found in sera from eight of 100 patients with Guillain–Barré syndrome (GBS) by the use of enzyme‐linked immunosorbent assay and thin‐layer chromatogram immunostaining. Those sera also had antibody activities to such ganglioside complexes as GD1a/GM1, GD1b/GT1b, and GM1/GT1b but had little or no reactivity to the each isolated antigen. Clustered epitopes of the ganglioside complex in the plasma membrane may be targeted by such an antibody, and interaction between the antibody and ganglioside complex may induce the neuropathy. Ann Neurol 2004</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380861294256408704","@type":"Researcher","foaf:name":[{"@value":"Ken‐ichi Kaida"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318352082822","@type":"Researcher","foaf:name":[{"@value":"Daiji Morita"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318352082821","@type":"Researcher","foaf:name":[{"@value":"Mami Kanzaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318352082820","@type":"Researcher","foaf:name":[{"@value":"Keiko Kamakura"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318352082818","@type":"Researcher","foaf:name":[{"@value":"Kazuo Motoyoshi"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318352082819","@type":"Researcher","foaf:name":[{"@value":"Minako Hirakawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670318352082816","@type":"Researcher","foaf:name":[{"@value":"Susumu Kusunoki"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"03645134"},{"@type":"EISSN","@value":"15318249"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/03645134"}],"prism:publicationName":[{"@value":"Annals of Neurology"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2004-08-31","prism:volume":"56","prism:number":"4","prism:startingPage":"567","prism:endingPage":"571"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fana.20222"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ana.20222"}],"createdAt":"2004-08-31","modifiedAt":"2023-10-17","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Immunoblotting","dc:title":"Immunoblotting"},{"@id":"https://cir.nii.ac.jp/all?q=Enzyme-Linked%20Immunosorbent%20Assay","dc:title":"Enzyme-Linked Immunosorbent Assay"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Guillain-Barre%20Syndrome","dc:title":"Guillain-Barre Syndrome"},{"@id":"https://cir.nii.ac.jp/all?q=Antibodies","dc:title":"Antibodies"},{"@id":"https://cir.nii.ac.jp/all?q=Gangliosides","dc:title":"Gangliosides"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Chromatography,%20Thin%20Layer","dc:title":"Chromatography, Thin Layer"},{"@id":"https://cir.nii.ac.jp/all?q=Gangliosidoses","dc:title":"Gangliosidoses"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050001202615126912","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"Guillain-Barre 症候群と自律神経障害"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002216027827072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004232298398208","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antibodies to LM1 and LM1-containing ganglioside complexes in Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004235493003904","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of acidic phospholipids on antiganglioside antibodies in <scp>G</scp>uillain–<scp>B</scp>arré syndrome: Role of the disialosyl residue"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013168764080384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Cholesterol-added antigens can enhance antiglycolipid antibody activity: Application to antibody testing"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285707120331008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Autoantibodies in neuroimmunological diseases; relevance of fine specificity"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285709567654656","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Anti-GM1/GD1a complex antibodies in GBS sera specifically recognize the hybrid dimer GM1-GD1a"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285711926812032","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Varied antibody reactivities and clinical relevance in anti-GQ1b antibody–related diseases"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285712543777920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Complex of GM1- and GD1a-Like Lipo-Oligosaccharide Mimics GM1b, Inducing Anti-GM1b Antibodies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285713014555008","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Guillain–Barré syndrome: update on immunobiology and treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1360306905611584256","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Co‐occurrence analysis of the correlation of antibodies to glycolipids or ganglioside complexes with clinical features: A retrospective cohort study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182251837056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"An antibody to the GM1/GalNAc-GD1a complex correlates with development of pure motor Guillain–Barré syndrome with reversible conduction failure"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185446788992","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Mechanism and spectrum of anti‐glycolipid antibody‐mediated chronic inflammatory demyelinating polyneuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118832811136","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Multifaceted features of immunoglobulin G anti‐GM1 antibodies in Guillain–Barré syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657228490624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antibodies to ganglioside complexes consisting of asialo-GM1 and GQ1b or GT1a in Fisher and Guillain–Barré syndromes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848657228500096","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antibodies to gangliosides and ganglioside complexes in Guillain–Barré syndrome and Fisher syndrome: Mini-review"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660591531392","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antibodies against ganglioside complexes in Guillain‐Barré syndrome and related disorders"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660685578240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Neuropathophysiological potential of Guillain-Barré syndrome anti-ganglioside-complex antibodies at mouse motor nerve terminals"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567482734080","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Antiglycolipid antibodies in Guillain-Barré and Fisher syndromes: discovery, current status and future perspective"}]},{"@id":"https://cir.nii.ac.jp/crid/1360853567837271168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Finger drop sign as a new variant of acute motor axonal neuropathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204651696512","@type":"Article","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Antiganglioside antibodies-Their pathophysiological effects on Guillain-Barre Syndrome and variants-"},{"@language":"ja","@value":"抗ガングリオシド抗体―ギラン・バレー症候群とその関連疾患における病態への関与―"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205035290368","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Guillain-Barré and Fisher syndromes: update on the pathophysiological role of antiganglioside antibodies"},{"@value":"ギラン・バレー症候群，フィッシャー症候群：抗ガングリオシド抗体の神経障害作用"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205036513408","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy","isCitedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Immune-mediated neuropathies"},{"@language":"ja","@value":"シンポジウム１２‐３　末梢神経疾患研究の現在　免疫介在性ニューロパチー"},{"@value":"免疫介在性ニューロパチー"},{"@language":"ja-Kana","@value":"メンエキ カイザイセイ ニューロパチー"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205037324672","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Galactocerebroside抗体のみが陽性であった純粋感覚型Guillain-Barré症候群の1例"},{"@language":"en","@value":"A case of pure-sensory-type Guillain-Barré syndrome with galactocerebroside antibody"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206445691520","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"8. Inflammatory and Peripheral Nerve Disorder (Autoimmune Peripheral Neuropathy)"},{"@language":"ja","@value":"8．炎症と末梢神経疾患（免疫性末梢神経障害について）"},{"@value":"炎症と末梢神経疾患(免疫性末梢神経障害について)"},{"@language":"ja-Kana","@value":"エンショウ ト マッショウ シンケイ シッカン メンエキセイ マッショウ シンケイ ショウガイ ニ ツイテ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206447649664","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"2) Pathogenesis and Treatment of Immune-mediated Neuropathies; the Cutting Edge"},{"@language":"ja","@value":"2）免疫性ニューロパチーの病態と治療の最前線"},{"@value":"免疫性ニューロパチーの病態と治療の最前線"},{"@language":"ja-Kana","@value":"メンエキセイ ニューロパチー ノ ビョウタイ ト チリョウ ノ サイゼンセン"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680011439232","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Immune-mediated neuropathy"},{"@language":"ja","@value":"シンポジウム１１‐２　末梢神経障害の研究‐最近の進歩‐　免疫関連性ニューロパチー"},{"@value":"免疫関連性ニューロパチー"},{"@language":"ja-Kana","@value":"メンエキ カンレンセイ ニューロパチー"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680011585792","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"A case of pure motor Guillain-Barre syndrome with motor conduction block and anti-GM1/GalNAc-GD1a antibody"},{"@language":"ja","@value":"抗ＧＭ１／ＧａｌＮＡｃ－ＧＤ１ａ複合体抗体陽性で，伝導ブロックを呈した純粋運動型Ｇｕｉｌｌａｉｎ－Ｂａｒｒｅ症候群の１例"},{"@value":"症例報告 抗GM1/GalNAcGD1a複合体抗体陽性で,伝導ブロックを呈した純粋運動型Guillan-Barre症候群の1例"},{"@language":"ja-Kana","@value":"ショウレイ ホウコク コウGM1 GalNAcGD1a フクゴウタイ コウタイ ヨウセイ デ デンドウ ブロック オ テイシタ ジュンスイ ウンドウガタ Guillan Barre ショウコウグン ノ 1レイ"},{"@value":"Case of pure motor Guillain–Barré syndrome with motor conduction block and anti-GM1/GalNAc-GD1a antibody"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680016450176","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"ガラクトセレブロシド・リン脂質複合体に対するIgG抗体陽性急性自律性感覚性ニューロパチーの1例"},{"@language":"en","@value":"A case of acute autonomic and sensory neuropathy (AASN) with antibody against a mixture of galactocerebroside and phospholipids"}]},{"@id":"https://cir.nii.ac.jp/crid/1390308365648358016","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Severe Recurrent Guillain-Barré Syndrome with Antibodies against Ganglioside Complexes Related to GQ1b and GD1b"}]},{"@id":"https://cir.nii.ac.jp/crid/1520572359410357120","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@value":"GBSにおける自律神経障害"},{"@language":"ja-Kana","@value":"GBS ニ オケル ジリツ シンケイ ショウガイ"}]},{"@id":"https://cir.nii.ac.jp/crid/1570572701272287360","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Pure motor Guillain-Barre 症候群の新規標的抗原 : GM1/GalNAc-GD1a複合体 : 電気生理所見を中心として"},{"@language":"en","@value":"GM1/GalNAc-GD1a complex as a new target antigen of pure motor Guillain-Barre syndrome : electrophysiological aspect"}]},{"@id":"https://cir.nii.ac.jp/crid/1571135651215591424","@type":"Article","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"Pure motor Guillain-Barre 症候群の新規標的抗原 : GM1/GalNAc-GD1a複合体 : 電気生理所見を中心として"},{"@language":"en","@value":"GM1/GalNAc-GD1a complex as a new target antigen of pure motor Guillain-Barre syndrome : electrophysiological aspect"}]},{"@id":"https://cir.nii.ac.jp/crid/1572824500310097792","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isCitedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"抗ガングリオシド抗体研究の新たな展開"},{"@language":"en","@value":"New aspect of research on antiganglioside antibodies"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1002/ana.20222"},{"@type":"CIA","@value":"30008830718"},{"@type":"OPENAIRE","@value":"doi_dedup___::583be2f3f3f390814447d4daf67841b3"},{"@type":"CROSSREF","@value":"10.1111/cen3.12002_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.49.488_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1016/j.jneuroim.2016.10.010_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1016/j.jneuroim.2021.577580_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1016/j.jneuroim.2009.06.017_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1093/glycob/cwr139_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1371/journal.pone.0124004_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1586/ern.09.77_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1016/j.jneuroim.2011.08.016_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1016/j.jneuroim.2012.09.005_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1016/j.jneuroim.2010.02.001_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.2169/naika.103.2105_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1111/cen3.70005_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1111/cen3.12452_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.2177/jsci.34.29_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1016/j.expneurol.2013.10.009_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.2169/naika.97.539_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.52.914_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.49.956_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1111/cen3.12653_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1111/j.1471-4159.2010.07029.x_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1111/j.1759-1961.2011.00022.x_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.48.1023_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.55.171_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1136/jnnp-2020-325053_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1002/mus.27126_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.6096-25_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.1212/nxi.0000000000000501_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"},{"@type":"CROSSREF","@value":"10.5692/clinicalneurol.cn-000914_references_DOI_XLzgMo7HV9FUTxTkQxGaAZmYV5c"}]}